SciELO - Scientific Electronic Library Online

 
vol.16 número3MRE in NAFLD: Promising but Further Validation is Required índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Annals of Hepatology

versão impressa ISSN 1665-2681

Resumo

CHINCHILLA-LOPEZ, Paulina; QI, Xingshun; YOSHIDA, Eric M.  e  MENDEZ-SANCHEZ, Nahum. The Direct-Acting Antivirals for Hepatitis C Virus and the Risk for Hepatocellular Carcinoma. Ann. Hepatol. [online]. 2017, vol.16, n.3, pp.328-330. ISSN 1665-2681.  http://dx.doi.org/10.5604/16652681.1235473.

The increase of incidences of Hepatocellular Carcinoma (HCC) will continue in the next decades. The therapies about hepatitis C infection has been questioned as a risk factor. Some authors emphasized that sustained virologic response (SVR) with interferon- based therapy reduced the risk of developing HCC. In contrast, some publications that to suggest an increasing risk of HCC in patients treated with Direct-Acting Antivirals (DAA). Whether these therapies are associated with an increased risk of HCC remains to be studied and continued long-term observational studies will be needed. The goal in HCV care needs to go beyond merely achieving an SVR.

Palavras-chave : Liver; Cancer; Drugs; Hepatitis.

        · texto em Inglês     · Inglês ( pdf )